https://www.pharmacytimes.com/view/loncastuximab-tesirine-demonstrates-promise-in-managing-hemophagocytic-lymphohistiocytosis-associated-with-diffuse-large-b-cell-lymphoma
The results indicate the potential use of loncastuximab tesirine as a treatment option for the rare hyperinflammatory condition.
loncastuximab tesirinedemonstratespromisemanaginglymphohistiocytosis
https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Marginal Zone B-cell Lymphoma.
swedish orphan biovitrumloncastuximab tesirinemarginal zone
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-loncastuximab-tesirine-lpyl-large-b-cell-lymphoma
On April 23, 2021, the Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a...
accelerated approvalloncastuximab tesirinefdagrantslarge